Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
- Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline
- Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate
Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced the appointment of Jean-Marie Cuillerot, M.D., as Chief Medical Officer (CMO).
